CClinicalTrials.gg
CompletedNCT01741818Updated Dec 5, 2012

The Cutoff Point for Caval Index and Its Correlation With Central Venous Pressure and Plasma Lactate Level for Assessing Patients in Hypovolemic Hemorrhagic States

An observational study in IVC Collapsibility Index and Hemorrhagic Shock, sponsored by Isfahan University of Medical Sciences. Completed at 2 sites in Iran, Islamic Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-05.

Sponsored by Isfahan University of Medical Sciences · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
106
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the cutoff point for IVC collapsibility index (by Bedside Ultrasonographic technique) for cases in hypovolemic hemorrhagic shock with CVP measures less than 8 cmH2o.

02

Conditions studied

  • IVC Collapsibility Index
  • Hemorrhagic Shock

Browse trials for

Keywords

  • IVC
  • ultrasonography
  • IVC collapsibility index
  • IVC diameter
03

In context

Shock, Hemorrhagic

78 studies on the registry are indexed under Shock, Hemorrhagic; 17 are open to participants now.

This study's enrollment of 106 is above the median of 94 across 30 observational studies indexed under Shock, Hemorrhagic.

Browse Shock, Hemorrhagic studies →

Lead sponsor

Isfahan University of Medical Sciences is the lead sponsor of 145 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

cases in hypovolemic hemorrhagic status (class II or more) that presented to our ED

Inclusion criteria

  • Hypovolemic hemorrhagic subjects (class II or more)if they were more than 18 years old and CVC insertion was indicated for them.

Exclusion criteria

Exclusion Criteria:

  • a history of Renal failure, Congestive Heart Failure, use of negative inotropic agents, presence of any contraindication for CVC insertion or failed ones and inability for measuring IVC by bUS were considered for exclusion.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
106 participants (actual)
Patient registry
No

Groups and cohorts

  • Group B

    CVP less than 8cmH2o

    Other: Measuring IVC collapsibility index by bedside ultrasonography

Interventions

  • OtherMeasuring IVC collapsibility index by bedside ultrasonography
06

What researchers measure

Primary outcomes

  1. IVC collapsibility index

    Time frame: within the first 5 minutes

Secondary outcomes

  1. Serum lactate level

    Time frame: within the first 5 minutes

07

Study locations

2 sites
  • Emergency Department of alzahra General Hospital, Isfahan University of Medical Sciences
    Isfahan, Iran, Islamic Republic of
  • Kerman University of Medical Sciences
    Kerman, Iran, Islamic Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01741818
Lead sponsor
Isfahan University of Medical Sciences
Responsible party
Keihan Golshani (Assistant Professor of Emergency Medicine, Isfahan University of Medical Sciences) — Principal investigator
First posted
Dec 5, 2012
Start date
Apr 2011
Primary completion
Jan 2012
Completion
Mar 2012
Last update
Dec 5, 2012

Study contacts

Keihan Golshani, MD.
study chair · Isfahan University of Medical Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion